Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (11-20 of 347) with videos related to

Pageof 35
Sort By:
JAMA Network Open|August 27, 2020
Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid TumorsLei Zhang, Xiaohong Han, Yuankai Shi
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|June 23, 2020
Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissuesLei Zhang, Xiaohong Han, Yuankai Shi
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|November 18, 2020
[Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer]Shasha Wang, Yuankai Shi, Xiaohong Han
Journal of Hematology & Oncology|November 28, 2025
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025)Liling Huang, Haohua Zhu, Yuankai Shi
Journal of Cancer Research and Therapeutics|October 7, 2022
Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancerJianping Xu, Xiaoyan Liu, Sheng Yang, et al.
Oncotargets and Therapy|April 28, 2021
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case ReportLin Gui, Shaoyan Liu, Ye Zhang, et al.
Oncology Research|October 16, 2019
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain MetastasesJianping Xu, Xiaoyan Liu, Sheng Yang, et al.
The Lancet Regional Health. Western Pacific|July 30, 2021
The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic reviewHaizhu Chen, Yu Zhou, Xiaohong Han, et al.
Scientific Data|December 18, 2024
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKINing Lou, Ruyun Gao, Yuankai Shi, et al.
Future Oncology (London, England)|March 17, 2021
Meta-analysis of the prognostic and clinical value of serum 25-hydroxyvitamin D levels in previously untreated lymphomaYunxia Tao, Haizhu Chen, Yu Zhou, et al.
Pageof 35

Showing results (11-20 of 347) with videos related to

Sort By:
Pageof 35
JAMA Network Open|August 27, 2020
Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid TumorsLei Zhang, Xiaohong Han, Yuankai Shi
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|June 23, 2020
Comparative analysis of SARS-CoV-2 receptor ACE2 expression in multiple solid tumors and matched non-diseased tissuesLei Zhang, Xiaohong Han, Yuankai Shi
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|November 18, 2020
[Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer]Shasha Wang, Yuankai Shi, Xiaohong Han
Journal of Hematology & Oncology|November 28, 2025
Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000-2025)Liling Huang, Haohua Zhu, Yuankai Shi
Journal of Cancer Research and Therapeutics|October 7, 2022
Efficacy, safety, and prognostic factors of apatinib plus platinum doublet chemotherapy in advanced non-small cell lung cancerJianping Xu, Xiaoyan Liu, Sheng Yang, et al.
Oncotargets and Therapy|April 28, 2021
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case ReportLin Gui, Shaoyan Liu, Ye Zhang, et al.
Oncology Research|October 16, 2019
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain MetastasesJianping Xu, Xiaoyan Liu, Sheng Yang, et al.
The Lancet Regional Health. Western Pacific|July 30, 2021
The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic reviewHaizhu Chen, Yu Zhou, Xiaohong Han, et al.
Scientific Data|December 18, 2024
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKINing Lou, Ruyun Gao, Yuankai Shi, et al.
Future Oncology (London, England)|March 17, 2021
Meta-analysis of the prognostic and clinical value of serum 25-hydroxyvitamin D levels in previously untreated lymphomaYunxia Tao, Haizhu Chen, Yu Zhou, et al.
Pageof 35